| abstract |
Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affiity and high selectivity to CRF1 receptors, including human CR F1 receptors. The invention thus includes methods for treatment of disorders an d diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chron ic neurological disorders and diseases. |